# Rapid Novor

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rapid-novor

- Industry: Biotechnology
- Headquarters: Kitchener, Canada
- Website: www.rapidnovor.com
- Total disclosed funding: $5M
- Latest round: Series A (Jul 28, 2020)
- Investors on record: 1

## About

Rapid Novor, Inc. is a biotechnology company established in 2015, specializing in antibody discovery and characterization through innovative sequencing technologies. Their solutions support advancements in therapeutic developments across various life sciences sectors.Founded in 2015 and headquartered in Kitchener, Ontario, Canada, Rapid Novor, Inc. focuses on the sequencing of antibodies without the need for hybridoma or DNA information. The company has not undergone any significant pivots or changes in operations since its inception. The firm raised USD 5.0 mn in Series A funding on July 28, 2020, led by Co-Win Ventures. Bin Ma is the founder, while Mingjie Xie serves as the CEO.Rapid Novor specializes in antibody characterization and discovery utilizing patented technology that enables the sequencing of antibodies from small protein samples without the need for hybridoma or DNA information. Their core offerings include monoclonal and polyclonal antibody sequencing, epitope mapping through mass spectrometry, and surface plasmon resonance for the label-free evaluation of antibody-antigen binding. These services empower biotech and pharmaceutical companies to achieve life science breakthroughs by providing insights into immune responses, optimizing antibody development, and facilitating the identification of high-quality therapeutic molecules. Rapid Novor serves over 650 clients across pharmaceuticals, biotechnology, and diagnostics, with a focus on markets in North America, Europe, and select regions in Asia. Their flagship test, EasyM, is CLIA accredited and used in clinical settings for tracking treatment responses in multiple myeloma patients.Rapid Novor operates primarily on a business-to-business (B2B) model, providing antibody sequencing and discovery services to clients in the pharmaceutical and biotech sectors. The firm engages in contract-based agreements where clients utilize its advanced technologies for specific research and development projects. Transactions are structured as fee-for-service engagements, with pricing plans tailored to project scopes. Rapid Novor’s proprietary services and technologies contribute to ongoing collaborations within the life sciences sector, enhancing its revenue streams.With the recent Series A funding of USD 5.0 mn raised in July 2020, Rapid Novor aims to enhance its operational capabilities and expand its product offerings. The company plans to develop new antibody characterization products and explore additional applications of their patented technologies. Furthermore, Rapid Novor is targeting expansion into new geographic markets across Europe and Asia by 2023, enhancing their service reach and client base.

## Funding rounds

- Series A, Jul 28, 2020, $5M — Co-Win Ventures

## Investors

- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series A